Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives.

Published on May 1, 2019in International Journal of Urology2.445
· DOI :10.1111/IJU.13943
Sean Berquist11
Estimated H-index: 11
(UCSD: University of California, San Diego),
Kendrick Yim7
Estimated H-index: 7
(UCSD: University of California, San Diego)
+ 10 AuthorsIthaar H. Derweesh43
Estimated H-index: 43
(UCSD: University of California, San Diego)
Sources
Abstract
: Systemic therapy strategies in the setting of localized and locally advanced renal cell carcinoma have continued to evolve in two directions: (i) as adjuvant therapy (to reduce the risk of recurrence or progression in high-risk localized groups); or (ii) as neoadjuvant therapy as a strategy to render primary renal tumors amenable to planned surgical resection in settings where radical resection or nephron-sparing surgery was not thought to be safe or feasible. In the realm of adjuvant therapy, the results of adjuvant therapy phase III randomized clinical trials have been mixed and contradictory; nevertheless, the findings of the landmark Sunitinib Treatment of Renal Adjuvant Cancer study have led to approval of sunitinib as an adjuvant agent in the USA. In the realm of neoadjuvant therapy, presurgical tumor reduction has been shown in a number of phase II studies utilizing targeted molecular agents and in a recently published small randomized double-blind placebo-controlled study, and an expanding body of literature suggests benefit in select patients. Thus, large randomized clinical trial data are not present to support this approach, and guidelines for use of presurgical therapy have not been promulgated. The advent of immunomodulation through checkpoint inhibition represents an exciting horizon for adjuvant and neoadjuvant strategies. The present article reviews the current status and future prospects of adjuvant and neoadjuvant therapy in localized and locally advanced renal cell carcinoma.
References51
Newest
#1Cedric LebacleH-Index: 8
#2Karim BensalahH-Index: 64
Last. Bernard EscudierH-Index: 106
view all 14 authors...
OBJECTIVE: To evaluate the ability of neoadjuvant axitinib to reduce the size of T2 renal cell carcinoma (RCC) for shifting from a radical nephrectomy (RN) to a partial nephrectomy (PN) indication, offering preservation of renal function. PATIENTS AND METHODS: Patients with cT2aN0NxM0 clear-cell RCC, considered not suitable for PN, were enrolled in a prospective, multicentre, phase II trial (AXIPAN). Axitinib 5 mg, and up to 7-10 mg, was administered twice daily, for 2-6 months before surgery, d...
13 CitationsSource
#1Charles Field (UCSD: University of California, San Diego)H-Index: 3
#2Brittney Cotta (UCSD: University of California, San Diego)H-Index: 7
Last. Ithaar H. Derweesh (UCSD: University of California, San Diego)H-Index: 43
view all 18 authors...
Abstract Background We analyzed outcomes of neoadjuvant sunitinib in patients with renal-cell carcinoma (RCC) and inferior vena caval (IVC) tumor and compared outcomes to patients who did not undergo neoadjuvant therapy before surgery. Patients and Methods We performed a multicenter retrospective comparison of RCC patients with IVC tumor who underwent neoadjuvant sunitinib before surgery versus those who did not. Response to sunitinib was defined by Response Evaluation Criteria in Solid Tumors (...
8 CitationsSource
#1Aly-Khan A. Lalani (McMaster University)H-Index: 12
#2Bradley Alexander McGregor (Harvard University)H-Index: 17
Last. Axel Bex (NKI-AVL: Netherlands Cancer Institute)H-Index: 54
view all 8 authors...
Abstract Context Systemic therapy for metastatic clear cell renal cell carcinoma (mccRCC) has greatly evolved over the last 15 yr. More recently, combination strategies involving contemporary immunotherapy have emerged as key opportunities to further shift the treatment landscape. Objective To review the evidence regarding the efficacy and safety of standard therapeutic options in mccRCC as well as combination immunotherapy options on the horizon. Evidence acquisition PubMed/Medline, Embase, Web...
82 CitationsSource
#1Marine Gross-GoupilH-Index: 26
#2Tae Gyun Kwon (KNU: Kyungpook National University)H-Index: 23
Last. David I. Quinn (SC: University of Southern California)H-Index: 72
view all 18 authors...
Abstract Background The ATLAS trial compared axitinib versus placebo in patients with locoregional renal cell carcinoma (RCC) at risk of recurrence after nephrectomy. Patients and methods In a phase III, randomized, double-blind trial, patients had >50% clear-cell RCC, had undergone nephrectomy, and had no evidence of macroscopic residual or metastatic disease [independent review committee (IRC) confirmed]. The intent-to-treat population included all randomized patients [≥pT2 and/or N+, any Fuhr...
85 CitationsSource
#1Freddie Bray (IARC: International Agency for Research on Cancer)H-Index: 18
#1Freddie Bray (IARC: International Agency for Research on Cancer)H-Index: 119
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
view all 6 authors...
This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer...
31.7k CitationsSource
#1Ahmet Bindayi (UCSD: University of California, San Diego)H-Index: 8
#2Zachary Hamilton (UCSD: University of California, San Diego)H-Index: 9
Last. Ithaar H. Derweesh (UCSD: University of California, San Diego)H-Index: 43
view all 9 authors...
Neoadjuvant Targeted Molecular Therapy in the setting of localized and locally advanced renal cell carcinoma has emerged as a strategy to render primary renal tumors amenable to planned surgical resection in settings where radical resection or nephron-sparing surgery was not thought to be safe or feasible. Presurgical tumor reduction has been demonstrated in a number of studies including a recently published randomized double-blind placebo-controlled study, and an expanding body of literature su...
28 CitationsSource
#1Robert J. Motzer (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 140
#2Alain RavaudH-Index: 77
Last. Michael StaehlerH-Index: 55
view all 21 authors...
Abstract Background Adjuvant sunitinib significantly improved disease-free survival (DFS) versus placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence after nephrectomy (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.59–0.98; p = 0.03). Objective To report the relationship between baseline factors and DFS, pattern of recurrence, and updated overall survival (OS). Design, setting, and participants Data for 615 patients randomized to sunitinib ( n = 30...
76 CitationsSource
#1Pedro C. Barata (Cleveland Clinic)H-Index: 15
#2Brian I. Rini (Cleveland Clinic Lerner College of Medicine)H-Index: 2
Answer questions and earn CME/CNE Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned from a nonspecific immune approach (in the cytokine era), to targeted therapy against vascular endothelial growth factor (VEGF), and now to novel immunotherapy agents. Multiple agents—including molecules against vascular endothelial growth factor, platelet-derived growth factor, and related receptors; inhibitors of other targets, such as the mammalian target of rapamycin an...
220 CitationsSource
#1Robert J. Motzer (UOU: University of Ulsan)H-Index: 140
#2Naomi B. Haas (UOU: University of Ulsan)H-Index: 36
Last. Cora N. Sternberg (UOU: University of Ulsan)H-Index: 98
view all 25 authors...
PurposeThis phase III trial evaluated the efficacy and safety of pazopanib versus placebo in patients with locally advanced renal cell carcinoma (RCC) at high risk for relapse after nephrectomy.Patients and MethodsA total of 1,538 patients with resected pT2 (high grade) or ≥ pT3, including N1, clear cell RCC were randomly assigned to pazopanib or placebo for 1 year; 403 patients received a starting dose of 800 mg or placebo. To address toxicity attrition, the 800-mg starting dose was lowered to ...
188 CitationsSource
#1Michelle L. McDonald (UCSD: University of California, San Diego)H-Index: 7
#2Brian R. Lane (Spectrum Health)H-Index: 60
Last. Ithaar H. Derweesh (UCSD: University of California, San Diego)H-Index: 43
view all 16 authors...
Abstract Background Sunitinib might optimize the feasibility of partial nephrectomy (PN) for complex renal tumors with imperative indications. We compared the renal functional outcomes of patients with complex renal masses who had undergone sunitinib before PN with those of patients who had not required neoadjuvant sunitinib before PN. Patients and Methods We performed a multicenter retrospective analysis of patients with renal cell carcinoma who had undergone PN for a complex renal mass (R.E.N....
5 CitationsSource
Cited By13
Newest
#1Wataru Shimada (Tokyo Medical and Dental University)
#2Hajime Tanaka (Tokyo Medical and Dental University)H-Index: 9
Last. Soichiro Yoshida (Tokyo Medical and Dental University)H-Index: 29
view all 0 authors...
OBJECTIVES Locally advanced renal cell carcinoma is considered clinically aggressive, despite heterogeneity in survival outcomes. We investigated the clinical relevance and pathological implications of infiltrative tumor interface with normal renal parenchyma on preoperative imaging in locally advanced renal cell carcinoma. METHODS A total of 77 patients with locally advanced renal cell carcinoma (≥pT3a Nany M0) who underwent radical or partial nephrectomy (2008-2018) were analyzed. Preoperative...
Source
#1Guillermo VelascoH-Index: 55
Last. Laurence Albiges (Université Paris-Saclay)H-Index: 58
view all 17 authors...
BACKGROUND No available data support the potential response of relapsed recurrent renal cell carcinoma (RCC) patients treated with systemic targeted therapies (TT) after completion of adjuvant sunitinib. In this study, we aimed to assess the efficacy and tolerability of rechallenge with sunitinib and other TT in advanced setting. METHODS In this multi-institutional retrospective study, relapsed RCC patients were re-challenged with sunitinib or other systemic TT as first-line therapeutic approach...
Source
#1Yudai IshiyamaH-Index: 2
#2Tsunenori KondoH-Index: 23
Last. Kazunari TanabeH-Index: 54
view all 6 authors...
OBJECTIVES To evaluate the outcomes of Japanese patients with renal cell carcinoma undergoing surgery for tumor thrombus invading the right atrium. METHODS We retrospectively evaluated 23 patients who underwent extracorporeal circulation-assisted surgery at two institutions. Perioperative outcomes and survival rates were evaluated and compared between two groups of patients, which were set according to the use or not of deep hypothermic circulatory arrest. Data on systemic treatments were assess...
Source
#1Stephen Ryan (UCSD: University of California, San Diego)H-Index: 8
#2Devin Patel (UCSD: University of California, San Diego)H-Index: 9
Last. Ithaar H. Derweesh (UCSD: University of California, San Diego)H-Index: 43
view all 13 authors...
BACKGROUND The impact of positive surgical margins (PSM) on outcomes in partial nephrectomy (PN) is controversial. We investigated impact of PSM for patients undergoing PN on overall survival (OS) in different stages of renal cell carcinoma (RCC). METHODS Retrospective analysis of patients from the US National Cancer Database who underwent PN for cT1a-cT2b N0M0 RCC between 2004-13. Patients were stratified by pathological stage [pT1a, pT1b, pT2a, pT2b, and pT3a (upstaged)] and analyzed by margin...
1 CitationsSource
#1Shingo Hatakeyama (Hirosaki University)H-Index: 27
#2Sei Naito (YU: Yamagata University)H-Index: 10
Last. Chikara Ohyama (Hirosaki University)H-Index: 37
view all 17 authors...
Objectives To compare overall survival between patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy and those not treated by cytoreductive nephrectomy. Methods We retrospectively evaluated 278 patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors between January 2008 and November 2019. Patients were divided into two groups: a cytoreductive nephrectomy group (immediate or deferred cytoreductive nephrectomy) and a group who r...
Source
#1Teijiro Hirashita (Oita University)H-Index: 12
#2Yukio Iwashita (Oita University)H-Index: 23
Last. Masafumi Inomata (Oita University)H-Index: 28
view all 7 authors...
BACKGROUND The treatment strategy for pancreatic metastasis (PM) from renal cell carcinoma (RCC) is unclear due to its rarity. The aim of this study was to reveal the role of surgery for PM from RCC. METHODS A systematic literature search was conducted using PubMed and the Cochrane Library. The effectiveness of surgery for PM was evaluated based on the primary outcome of overall survival (OS), which was investigated in relation to surgical procedures and metastatic sites via subgroup analyses. R...
2 CitationsSource
#1Jie Zhu (Peking Union Medical College)
#2Xiaojie Luo (Peking Union Medical College)H-Index: 1
Last. Min Chen (Peking Union Medical College)H-Index: 7
view all 6 authors...
Background To probe the feasibility and reproducibility of diffusion kurtosis tensor imaging (DKTI) in renal cell carcinoma (RCC) and to apply DKTI in distinguishing the subtypes of RCC and the grades of clear cell RCC (CCRCC). Methods Thirty-eight patients with pathologically confirmed RCCs [CCRCC for 30 tumors, papillary RCC (PRCC) for 5 tumors and chromophobic RCC (CRCC) for 3 tumors] were involved in the study. Diffusion kurtosis tensor MR imaging were performed with 3 b-values (0, 500, 1000...
Source
#1Sung-Han KimH-Index: 58
#2Boram Park (SMC: Samsung Medical Center)H-Index: 1
Last. Jinsoo ChungH-Index: 19
view all 8 authors...
This retrospective, five-multicenter study was aimed to evaluate the prognostic impact of pathologic nodal positivity on recurrence-free (RFS), metastasis-free (MFS), overall (OS), and cancer-specific (CSS) survivals in patients with non-metastatic renal cell carcinoma (nmRCC) who underwent either radical or partial nephrectomy with/without LN dissection. A total of 4236 nmRCC patients was enrolled between 2000 and 2012, and followed up through the end of 2017. Survival measures were compared be...
Source
#1Alberto MartiniH-Index: 27
#2Giuseppe FallaraH-Index: 3
Last. Umberto CapitanioH-Index: 62
view all 8 authors...
OBJECTIVE The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving. The aim of this review is to summarize the randomized-controlled trials evaluating the role of immunotherapy in neoadjuvant or adjuvant setting. MATERIALS AND METHODS We searched PubMed, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for studies including neoadjuvant or adjuvant immunotherapy, and provided a brief overview of the pharmacodynamics of immunotherapy for RCC. RESULTS Several...
2 CitationsSource
#1Yingkun Xu (SDU: Shandong University)H-Index: 6
#2Guangzhen Wu (Dalian Medical University)H-Index: 6
Last. Qinghua Xia (SDU: Shandong University)H-Index: 5
view all 10 authors...
Purpose To evaluate the expression of tripartite motif-containing 33 (TRIM33) in ccRCC tissues and explore the biological effect of TRIM33 on the progress of ccRCC. Method The Cancer Genome Atlas (TCGA) database was used to examine the mRNA expression levels of TRIM33 in ccRCC tissues and its clinical relevance. Immunohistochemistry (IHC) was performed to evaluate its expression in ccRCC tissues obtained from our hospital. The correlation between TRIM33 expression and clinicopathological feature...
2 CitationsSource